Axona®has been studied in clinical trials involving patients with mild to moderate Alzheimer’s disease as well as healthy elderly volunteers. The following is an overview of the results.

CLINICAL STUDY IN PATIENTS WITH PROBABLE MILD TO MODERATE ALZHEIMER’S DISEASE

Axona was evaluated in a double-blind, randomized, placebo-controlled study performed at multiple US clinical centers with 152 patients with mild to moderate Alzheimer’s disease over a period of 90 days. Approximately 80% of those participating were taking approved AD medications. The results showed a significant improvement in cognitive function in certain patients taking Axona while a decline was demonstrated in the placebo group. The results also showed that cognitive benefits could be maintained over a period of time in the patients receiving Axona.

SINGLE-DOSE STUDY

A study was conducted on 20 patients diagnosed with Alzheimer’s disease or mild cognitive impairment. The results showed a positive response with improvement in paragraph recall (a primary measure of cognition).

For complete information on the Axona randomized, double-blind, placebo-controlled multicenter study, please CLICK HERE

References: 1. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009;6:31.
2.Reger MA, Henderson ST, Hale C, et al. Effects of -hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 004;25(3):311-314.